Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).
Journal: Frontiers in oncology
Published: January 28, 2026
Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and Taxane Chemotherapy.
Journal: Clinical case reports
Published: November 11, 2025
Multiple Primary Acral Lentiginous Melanomas With BRCA1 Mutation.
Journal: JAAD case reports
Published: October 13, 2025
Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Journal: Therapeutic advances in medical oncology
Published: September 08, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Development of Poliosis in Patients Treated With Immunotherapy for Metastatic Cutaneous and Non-Cutaneous Melanoma.
Journal: Pigment cell & melanoma research
Published: April 28, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.
Journal: Pigment cell & melanoma research
Published: April 27, 2025
Chemoimmunotherapy in Advanced, PD-1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases.
Journal: Case reports in oncological medicine
Published: April 08, 2025
Last Updated: 09/26/2026